Copy
DAWN Rheumatology - January 2017 Newsletter
4S Information Systems Ltd

January 2017 DAWN Rheumatology Software E-Newsletter

In this issue:


Work Smarter - DAWN Version 7.9.61

NEW - Concurrent User Warning
DAWN RH will now display a Concurrent User Warning to a user when opening a patient record that is already being viewed by other DAWN users. A popup box will be displayed showing the name of the user(s) already viewing the same patient record.



A warning banner will be displayed at the top of the patient record at all times whilst the user is on the same patient record as another user. The banner has a link button called Show Users which can be clicked to refresh the patient record and check which users are still viewing the same patient record.



This feature will help to prevent key patient data being lost due to you being unable to save your changes because the record has already been changed and saved by another user while you were typing your changes. 

Improvement to Drug Drop Down List 
In previous versions of DAWN the drug drop down list displayed drugs marked as not in use.

Version 7.9.61 has changed this so that the only drugs included in the drop down list are drugs that are marked as 'in use' within the system settings. 

For more information about upgrading your DAWN RH system to the latest version, which is included as part of your annual maintenance contract, contact the 4S DAWN team at support@4s-dawn.com or +44 (0) 15395 63091. 


Join us for the latest DAWN Regional User Group - South Region
After the success of recent DAWN regional workshops in the Midlands and the North East, Imperial Healthcare, London, has kindly agreed to host the latest DAWN regional workshop - South Region, on Tuesday 21st February 2017.

The day will follow a similar format to previous meetings, running 10am - 3pm and including some customer presentations, networking/open discussion on current and future service challenges, and training sessions. 

Agenda:
10.00 – 10.20
Welcome & Introductions

10.20 – 10.40
Using technology to support patients with long term conditions
Colin Beevor, Queen Alexandra Hospital, Portsmouth

10.40 – 11.00
Working with DAWN: person or system?
Diane Home, West Middlesex Hospital, Middlesex

11.00 – 11.20
Immunosuppressants in Gastroenterology
Patsy Daly, Great Western Hospital, Swindon

11.20    – 12.00 
Discussion Forum: 
The challenges of new drugs and monitoring patients; Safety benefits of DAWN; Key challenges your service will face over the next five years

12.00 – 12.30
Improvements and Developments in DAWN
Alistair Stewart, 4S DAWN Clinical Software

12.30 – 13.00        
Lunch

13.00 – 15.00        
3 x 20min Training/10min Q&A Sessions (with refreshment/open discussion break)

15.00             
Close


If you would like to attend the user group or have any questions, please let me know at melissa@4s-dawn.com.

Please feel free to invite any of your colleagues from other departments who are involved in monitoring patients on Disease Modifying Agents and Biologics. 

We hope you can join us! 


Customer Support Resources
4S DAWN Clinical Software are committed to providing the best possible support service and resources to ensure that you get the most out of your system. As such, there are a number of support resources available to all of our customers:

Support Webpage:
Provides a range of support documents, user manuals, checklists and trouble-shooting guides.
http://www.4s-dawn.com/products/rheumatology/customer-support-resources/

Training Webpage:
A range of training videos that guide you through common workflows including ‘Adding treatment history’, ‘Making diary adjustments’, ‘rescheduling a next appointment’ and many more useful topics.
http://www.4s-dawn.com/customer-training-education/

Help Manual:
Access the E-Manual via your DAWN system by clicking on the ’Help’ button on the top left of the screen within your DAWN system.

Case Studies:
Read examples of how customers have used the DAWN system to improve efficiency, patient safety / experience, non-attenders and more.
http://www.4s-dawn.com/customers-case-studies/case-studies/

Customer Support Desk:
You can also contact the 4S DAWN support team directly who are on hand to help:

The support desk is open Monday - Friday, 9.00am - 5.30pm (UK) excluding public holidays
Email: support@4s-dawn.com        
Phone: (UK) 015395 63091
            (Outside UK) +44 15395 63091


Expand your capabilities with DAWN
There are a number of add-on modules available for DAWN RH designed to help customers expand their capabilities and improve productivity and efficiency. The following modules are available for DAWN RH systems:

  • Questionnaires
  • Interfaces - test results, demographics, admission and discharge, GP summary, medications and many more

For more information about any of the additional modules, contact the 4S DAWN team today - sales@4s-dawn.com.

As the range of application areas covered by 4S DAWN Clinical Software increases, there has been lots of interest in using DAWN within other departments and many customers now have a number of DAWN systems installed within their hospital/Trust.

The DAWN software also covers the following areas:

  • Anticoagulation
  • Anaemia Management
  • Clinical Haematology
  • Dermatology
  • Gastroenterology
  • Heart Failure
  • Multiple Sclerosis
  • Respiratory
  • VTE Diagnosis and Assessment
If you or any of your colleagues would be interested in learning more about any of the areas above, contact the 4S DAWN team today at sales@4s-dawn.com to discuss your requirements and see a demonstration of the software in action.



Did you know.....
RA Treatment with TNF Inhibitors Greatly Decreases Heart Attack Risk, UK Study Finds
The risk of heart attack associated with rheumatoid arthritis (RA) may decrease by nearly half when TNF inhibitors (TNFi) are part of the treatment, according to new research conducted at the University of Manchester, United Kingdom.

Patients with RA have a 60% higher risk of heart attacks than the general public. The higher risk is believed to be related to joint inflammation, which leads to the development of blood vessel anomalies (that then can affect blood flow). Current available treatments to reduce inflammation associated with RA include TNFi drugs, which work by decreasing the activity of inflammatory proteins, and synthetic disease-modifying therapies (sDMARDs), such as methotrexate, which delay disease progression
https://rheumatoidarthritisnews.com/2017/01/16/rheumatoid-arthritis-treatment-tnf-inhibitors-decrease-heart-attack/


NICE backs use of UCB’s Cimzia, Novartis’ Cosentyx for psoriatic arthritis
Cost regulators for the NHS in England and Wales are backing UCB's Cimzia and Novartis' Cosentyx as treatment options for adults with active psoriatic arthritis.

The National Institute for Health and Care Excellence is supporting use of Cimzia (certolizumab pegol) alone, or in combination with methotrexate, if the person has had a TNF-alpha inhibitor but their disease has stopped responding after the first 12 weeks, and the drug is provided under the conditions of a patient access scheme.

Cosentyx (secukinumab) is also recommended alone, or in combination with methotrexate, in the same circumstances, and also if TNF-alpha inhibitors are contraindicated but would otherwise be considered.
http://www.pharmatimes.com/news/nice_backs_use_of_ucbs_cimzia,_novartis_
cosentyx_for_psoriatic_arthritis_1183443



MRI Predicts Joint Damage in Rheumatoid Arthritis
Changes in joint damage and inflammation, detected with magnetic resonance imaging (MRI) as early as 12 weeks, predict changes in joint damage evident on subsequent x-rays in patients with rheumatoid arthritis (RA), new research has found.

In the study, published in the Annals of the Rheumatic Diseases, the authors, led by Charles Peterfy, MD, PhD, founder and CEO of Spire Sciences Inc., in Boca Raton, Fla., recommend using MRI to assess inflammation and joint damage in short-duration randomized controlled trials (RCTs) in RA.

"MRI is a valid imaging method for evaluating inflammation and joint damage in rheumatoid arthritis, and it detects changes in these disease features earlier than radiography does," Peterfy told MedPage Today. "MRI should be accepted for evaluating structure-modifying treatment efficacy in phase III clinical trials."
http://www.medpagetoday.com/mastery-of-medicine/rheumatology-mastery-in-ra/62292


RA: Taking Aim at Comorbidities
Researchers from the Mayo Clinic have been addressing important concerns about comorbidities in patients with rheumatoid arthritis, including risks of infection associated with interstitial lung disease (ILD) and measurement of diastolic dysfunction as a predictor of heart failure.

Two of their experts, Eric L. Matteson, MD, and John M. Davis III, MD, discuss recent studies about these topics published online in a supplement to Arthritis & Rheumatology.
http://www.medpagetoday.com/mastery-of-medicine/rheumatology-mastery-in-ra/62281

Follow Us On Our LinkedIn Company Page
To keep up to date with all the latest news and developments, join our LinkedIn community and follow 4S DAWN Clinical Software.

 
Copyright © 2017 4S Information Systems Ltd, All rights reserved.